



COVANCE

by user - facilities distributors and
retailers for MANDATORY reporting

FDA Facsimile Approval 8/13/96

Mfr report #	8287900
UF/Dist report #	
FDA Use Only	

Page - 1 - of 1

A. Patient information

1. Patient Identifier UNK 8287900 In confidence	2. Age at time of event: 16 or Date of birth:	3. Sex <input checked="" type="checkbox"/> female <input type="checkbox"/> male	4. Weight UNK lbs or kg
--	---	---	----------------------------------

B. Adverse event or product problem

1. <input checked="" type="checkbox"/> Adverse event and/or <input type="checkbox"/> Product problem (e.g., defects/malfunctions)	
2. Outcomes attributed to adverse event (check all that apply)	
<input type="checkbox"/> death (mo/day/yr)	<input type="checkbox"/> disability
<input type="checkbox"/> life-threatening	<input type="checkbox"/> congenital anomaly
<input checked="" type="checkbox"/> hospitalization-initial or prolonged	<input type="checkbox"/> required intervention to prevent permanent impairment/damage
<input type="checkbox"/> other:	
3. Date of event (mo/day/yr) 03/05/2001	4. Date of this report (mo/day/yr) 03/13/2001

5. Describe event or problem

Information has been received from an emergency room nurse via Pittsburgh Poison Center regarding a 16-year-old female consumer who had ingested an unknown amount of Aleve and 20 gms of Tylenol on 05-Mar-2001. The consumer began vomiting and continued for 2 days. She was evaluated in the emergency room on 08-Mar-2001 for complaints of bilateral flank pain. Her urine was positive for blood and elevated protein. She appeared dehydrated. She was treated with intravenous fluids, 17 doses of N-acetylcysteine and Reglan (metoclopramide hydrochloride) as needed. On 08-Mar-2001 at 7 PM, lab test results included an ALT (alanine transaminase) level of 81 U/mL, an AST (aspartate transaminase) level of 54 U/mL, drug screen, APAP (acetaminophen) and ASA (acetylsalicylic acid) levels were all negative. On 09-Mar-2001, an ALT level was 48 U/mL and an AST level was 26 U/mL. Medical history and concomitant therapy were not provided. If additional information is obtained, it will be forwarded.

6. Relevant tests/laboratory data, including dates

08-Mar-2001: urine was positive for blood and elevated protein level. 08-Mar-2001: ALT=81 U/mL; AST=54 U/mL; drug screen, APAP and ASA levels were all negative. 09-Mar-2001: ALT=48 U/mL; AST=26 U/mL.

7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

None Provided

C. Suspect medication(s)

1. Name (give labeled strength & mfr/labeler, if known)	
#1 ALEVE - Any Type	
#2 Tylenol	
2. Dose, frequency & route used	3. Therapy dates (if unknown, give duration) from/to (or best estimate)
#1 UNK ORAL 01X	#1 03/05/2001 - 03/05/2001
#2 UNK ORAL 01X	#2 03/05/2001 - 03/05/2001
4. Diagnosis for use (indication)	6. Event abated after use stopped or dose reduced
#1 Unknown	#1 <input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> n/a
#2 Unknown	#2 <input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> n/a
6. Lot # (if known)	7. Exp. date (if known)
#1 UNK	#1 UNK
#2 UNK	#2 UNK
9. NDC # for product problems only (if known)	
10. Concomitant medical products and therapy dates (exclude treatment of event)	
None Provided	

G. All manufacturers

1. Contact office - name/address (& mfring site for devices)		2. Phone number (973) 254-5000
Bayer Corporation 36 Columbia Road P.O. Box 1910 Morristown, NJ 07962-1910		3. Report Source (check all that apply)
4. Date received by manufacturer (mo/day/yr) 03/09/2001		<input type="checkbox"/> foreign
5. (A)NDA # 20 - 204		<input type="checkbox"/> study
6. IND, protocol #		<input type="checkbox"/> literature
7. Type of report (check all that apply)		<input type="checkbox"/> consumer
<input type="checkbox"/> 5-day <input checked="" type="checkbox"/> 15-day		<input checked="" type="checkbox"/> health professional
<input type="checkbox"/> 10-day <input type="checkbox"/> periodic		<input type="checkbox"/> user facility
<input checked="" type="checkbox"/> initial <input type="checkbox"/> follow-up # 0		<input type="checkbox"/> company representative vs
8. pre-1938 <input type="checkbox"/> OTC product <input checked="" type="checkbox"/>		<input type="checkbox"/> distributor
9. Mfr. report number 8287900		<input type="checkbox"/> other:
1. Adverse event term(s) OVERDOSE; VOMITING; BACK PAIN; HEMATURIA; ALBUMINURIA; DEHYDRATION; SGOT PT INCREASED; SGOT INCREASED		

E. Initial reporter

1. Name, address & phone # UNK		DSS
		MAR 21 2001
2. Health professional? <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	3. Occupation NURSE	4. Initial reporter also sent report to FDA <input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> unk



Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

MAR 20 2001